DexCom (DXCM) Tops Q3 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
DexCom (DXCM) PT Raised to $655 at Jefferies
October 29, 2021 7:43 AM EDTJefferies analyst Raj Denhoy raised the price target on DexCom (NASDAQ: DXCM) to $655.00 (from $610.00) while maintaining a Buy rating.
The analyst commented, "XCM posted a $31mn/$0.25 beat on accelerating T2 adoption and OUS momentum which was supplemented by G&A leverage gains.... More
